PREVENTIVE OR THERAPEUTIC AGENT FOR PSORIASIS COMPRISING IL-6 ANTAGONIST AS ACTIVE INGREDIENT

• US 20080124325A1
• Filed: 11/29/2007
• Published: 05/29/2008
• Est. Priority Date: 10/25/2000
• Status: Active Grant

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Inventors: Akamatsu, Kenichi, Sugimoto, Masamichi, Ito, Hiroaki, Yoshizaki, Kazuyuki, Kitamura, Hidetomo, Kishimoto, Tadamitsu, Shimaoka, Shin, Nishimoto, Norihiro
• Granted Patent: US 8,597,644 B2
• Time in Patent Office: Days
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A method for treating psoriasis comprising an interleukin-6 (IL-6) antagonist such as, for example, an antibody against IL-6 receptor.

Claims

1. A method for treating psoriasis comprising administering an effective amount of an antibody against interleukin-6(IL-6) receptor to a subject in need thereof, wherein said antibody is an antibody which is capable of blocking a binding between IL-6 and IL-6 receptor, and blocking signal transduction by IL-6.

2. The method of claim 1, wherein IL-6 receptor is a human IL-6 receptor.

3. The method of claim 1, wherein the antibody is a monoclonal antibody.

4. The method of claim 1, wherein the antibody is a recombinant antibody.

5. The method of claim 1, wherein the antibody is a humanized antibody.

6. The method of claim 1, wherein the antibody is a human antibody.